Because inflammatory factors such as IL‐1β, TNF‐α, and cell adhesion molecules that regulate extravasation of leukocytes were reported to mediate their recruitment to inflammation sites [49], the delivery of EGCG to tumor vasculature using RGD‐MEND may inhibit vascular inflammation with the inhibition of CD45‐positive leukocyte infiltration. This evidence concerns the gene IL1B and neoplasm.